A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 (1.0% Azithromycin and 0.1% Dexamethasone) Compared to AzaSite Alone, Dexamethasone 0.1% Alone, and Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis

Trial Profile

A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 (1.0% Azithromycin and 0.1% Dexamethasone) Compared to AzaSite Alone, Dexamethasone 0.1% Alone, and Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2015

At a glance

  • Drugs Azithromycin/dexamethasone (Primary) ; Azithromycin; Dexamethasone
  • Indications Blepharitis
  • Focus Registrational; Therapeutic Use
  • Acronyms DOUBle
  • Sponsors InSite Vision
  • Most Recent Events

    • 08 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top